Here’s what you should know.
1. Shire creates pharmaceutical treatments for rare diseases and hyperactivity.
2. The rumors sent Shire’s stock price rocketing. The drug maker’s stock rose 25 percent March 27.
3. Shire is valued at $46.3 billion (£32.7 billion).
4. Takeda confirmed to CNBC its approach was at a preliminary and exploratory stage. Takeda will have until April 25 to make a bid.
More articles on coding, billing and collections:
Readers push back on ‘sensationalized’ story misrepresenting ASC safety — 5 insights
3 ways ASCs can capitalize on the transition to outpatient care
Drugmaker paid roughly $550K to lobby for ASC, outpatient reimbursement status
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
